Skip to content

Zymeworks ZYME Lessee Operating Lease Liability Undiscounted Excess Amount

Lessee Operating Lease Liability Undiscounted Excess Amount at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
iRhythm Holdings, Inc.
 logo
iRhythm Holdings, Inc. IRTC

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total debt$17.0M-7.7%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.76B+125%
Enterprise value$1.53B+112%
P/S21.6×+13.2×

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's lessee operating lease liability undiscounted excess amount.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zymeworks's lessee operating lease liability undiscounted excess amount?
Zymeworks (ZYME) reported lessee operating lease liability undiscounted excess amount of $2.35M in Q1 2026.
How has Zymeworks's lessee operating lease liability undiscounted excess amount changed year-over-year?
Zymeworks's lessee operating lease liability undiscounted excess amount decreased by 14.4% year-over-year, from $2.75M to $2.35M.